17-AAG

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

一种有效的 Hsp90 抑制剂，在无细胞测定中 IC50 为 5 nM。

A potent Hsp90 inhibitor with IC50 of 5 nM in cell-free assays; induces cytosolic accumulation of cytochrome c and cleavage and activities of caspase-9 and caspase-3, triggering apoptosis of HL-60/Bcr-Abl and K562 cells; causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor; inhibits prostate cancer xenografts growth in mice.Skin Cancer Phase 2 Discontinued(In Vitro):Tanespimycin causes the degradation of HER2, Akt, and both mutant and wild-type AR and the retinoblastoma-dependent G1 growth arrest of prostate cancer cells. Tanespimycin inhibits prostate cancer cell lines with IC50s ranged from 25-45 nM (LNCaP, 25 nM; LAPC-4, 40 nM; DU-145, 45 nM; and PC-3, 25 nM).Tanespimycin (0.1-1 μM) induces a nearly complete loss of ErbB2 on ErbB2-overexpressing breast cancer cells. Tanespimycin inhibits cell growth and induces G2/M cell cycle arrest and apoptosis in CCA cells together with the down-regulation of Bcl-2, Survivin and Cyclin B1, and the up-regulation of cleaved PARP.(In Vivo):Tanespimycin (25-200 mg/kg, i.p.) causes a dose-dependent decline in AR, HER2, and Akt expression in prostate cancer xenografts. Tanespimycin treatment at doses sufficient to induce AR, HER2, and Akt degradation results in the dose-dependent inhibition of androgen-dependent and -independent prostate cancer xenograft growth without toxicity.Tanespimycin (60 mg/kg) with Rapamycin (30 mg/kg) inhibits A549 and MDA-MB-231 tumor growth and effects tumor cures in MDA-MB-231 tumor-bearing animals by tail vein injection.

——

——

Tanespimycin | NSC 330507 | CP 127374 | 17AAG | 17 AAG

Cytoskeleton/Cell Adhesion Molecules

HSP

HSP90

Cancer

Skin Cancer

75747-14-7

585.6884

C31H43N3O8

>98% (HPLC)

DMSO: ≥ 55 mg/mL

NC(O[C@@H](/C(C)=C/[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC1=C2NCC=C)[C@@H](OC)/C=C/C=C(C)/C(NC(C1=O)=CC2=O)=O)=O

Geldanamycin, 17-demethoxy-17-(2-propenylamino)-

(-20℃)

With Ice Pack

≥ 2 years